Passive targeting

Dear Friends, I want to explain the principles of targeting in a brief manner.

Dear Pharmainfo.net friends No more blogging on prices and policies. We are going to prove that we are Pharmaceutical Scientists (who are Jacks of all Trades but are Masters of All trades) by writing on the following topics: Leader: The principles of targeting Santosh: Targeting to the tumour Nikilesh: Targeting to the brain Kranthi: Targeting to bone marrow

Dear Pharmainfo friends

INTRODUCTION:

In the month of May we , the Atharvanas, would like to focus on the following topics:

Team topic--- Prices of medicines

Leader--- Drug prices -an international comparison; cases relating to prices

Santosh- Policies to control prices (international scenario)

Kranthi--Drug prices- brands vs generics

Dear Pharmainfo.net friends It has taken me a long time to write this blog for three reasons. * I have been busy as a bee. * This is a topic I have been researching on and I can never bring myself to say "this is enough".

Hello friends, We now find that we have a lot more to tell you all regarding bioavailability and bioequivalence. Hence we choose to continue to focus on it in the month of April also. Following is the allotment of topics. Kranthi ---------- Factors affecting Bioavailability Niklesh ---------- Biowaivers Santosh ---------- Bioequivalence from the regulatory perspective

Research into Bioequivalence Dear friends in the quest for valuable knowledge Welcome to another shot of research work on bioequivalence (BE). Bioequivalence work will be going on all the time.